 <h1>Naloxone / oxycodone Side Effects</h1><ul class="nav-tabs nav-tabs-collapse nav-tabs-pill">
<li>Overview</li>
<li><b class="nav-item here">Side Effects</b></li>
<li>Dosage</li>
<li>Interactions</li>
<li>Pregnancy</li>
<li>Reviews</li>
<li class="nav-more">
More&lt;svg aria-hidden="true" class="ddc-icon ddc-icon-down" focusable="false" height="16" viewbox="0 0 24 24" width="16" xmlns="http://www.w3.org/2000/svg"&gt;&lt;path d="M18.5 7.94L19.56 9 12 16.56 4.44 9 5.5 7.94l6.5 6.5z"&gt;&lt;/path&gt;&lt;/svg&gt;
</li>
</ul><ul>
<li>Managing Side Effects</li>
</ul><p><i>Applies to naloxone/oxycodone: oral tablet extended release</i></p><h3>Cardiovascular</h3><p><b>Common</b> (1% to 10%): Hypertension, hypotension </p><p><b>Uncommon</b> (0.1% to 1%): Angina pectoris, (especially in patients with history of coronary artery disease), palpitations, peripheral edema, chest pain</p><p><b>Rare</b> (less than 0.1%): Syncope</p><p><b>Frequency not reported</b>: Flushing, bradycardia, ST depression, supraventricular tachycardia<sup>[Ref]</sup></p><h3>Dermatologic</h3><p><b>Common</b> (1% to 10%): Pruritus, rash, cold sweat</p><p><b>Postmarketing reports</b>: Hyperhidrosis, exfoliative dermatitis, dry skin, urticaria<sup>[Ref]</sup></p><h3>Endocrine</h3><p><b>Common</b> (1% to 10%): Hot flush<sup>[Ref]</sup></p><h3>Gastrointestinal</h3><p><b>Common</b> (1% to 10%): Diarrhea, abdominal pain, dry mouth, flatulence, vomiting, nausea, anorexia, increased appetite, gastroenteritis, dyspepsia, constipation</p><p><b>Frequency not reported</b>: Thirst, eructation, colic, dysphagia, stomatitis, taste perversion, dental caries, ileus, flatulence<sup>[Ref]</sup></p><h3>Genitourinary</h3><p><b>Frequency not reported</b>: Urinary tract infection, micturition urgency, ureteric spasm, erectile dysfunction, urinary retention, amenorrhea<sup>[Ref]</sup></p><h3>Hepatic</h3><p><b>Frequency not reported</b>: Biliary colic, increased liver enzymes, biliary spasm, cholestasis<sup>[Ref]</sup></p><h3>Hypersensitivity</h3><p><b>Rare</b> (less than 0.1%): Allergic reactions, anaphylactic reactions<sup>[Ref]</sup></p><h3>Immunologic</h3><p><b>Common</b> (1% to 10%): Influenza</p><p><b>Rare</b> (less than 0.1%): Herpes simplex</p><p><b>Frequency not reported</b>: Lymphadenopathy<sup>[Ref]</sup></p><h3>Metabolic</h3><p><b>Common</b> (1% to 10%): Loss of appetite </p><p><b>Rare</b> (less than 0.1%): Dehydration, increased appetite</p><p><b>Frequency not reported</b>: Increased serum triglycerides, hyponatremia<sup>[Ref]</sup></p><h3>Musculoskeletal</h3><p><b>Common</b> (1% to 10%): Back pain, fall, arthralgia, myalgia</p><p><b>Frequency not reported</b>: Myalgia, neck pain, striated and nonstriated muscle spasms, muscle twitching, muscle rigidity, osteoarthritis, abnormal gait, hypertonia, involuntary muscle contractions, abnormal coordination<sup>[Ref]</sup></p><h3>Nervous system</h3><p><b>Common</b> (1% to 10%): Headache, fatigue, dizziness, drug withdrawal syndrome, sedation, tremor, sinus headache, somnolence</p><p><b>Uncommon</b> (0.1% to 1%): Disturbance in attention, paraesthesia, speech disorder, malaise</p><p><b>Rare</b> (less than 0.1%): Convulsions (particularly in persons with epileptic disorder or predisposition to convulsions)</p><p><b>Frequency not reported</b>: Syncope</p><p><b>Postmarketing reports</b>: Raised intracranial pressure, sciatica, tremor, vertigo, drowsiness, paraesthesia, somnolence, speech disorder, amnesia, hypertonia, migraine, feeling hot and cold, chills, tinnitus<sup>[Ref]</sup></p><h3>Ocular</h3><p><b>Common</b> (1% to 10%): Lacrimation increased</p><p><b>Uncommon</b> (0.1% to 1%): Visual disturbances, miosis<sup>[Ref]</sup></p><h3>Oncologic</h3><p><b>Common</b> (1% to 10%): Malignant neoplasm progression</p><h3>Psychiatric</h3><p><b>Common</b> (1% to 10%): Drug abuse, anxiety, restlessness</p><p><b>Uncommon</b> (0.1% to 1%): Abnormal thinking, confusion, depression, hallucination, altered mood, personality change, euphoric mood, decreased activity, psychomotor hyperactivity, agitation, nervousness, insomnia, perception disturbances (e.g., hallucination, derealization), reduced libido, mood changes, disorientation, dysphoria, nightmares<sup>[Ref]</sup></p><h3>Respiratory</h3><p><b>Common</b> (1% to 10%): Dyspnea, rhinorrhea, yawning</p><p><b>Uncommon</b> (0.1% to 1%): Respiratory depression, bronchial spasm, spasms of nonstriated muscles, suppression of the cough reflex</p><p><b>Frequency not reported</b>: Bronchitis, nasopharyngitis, pharyngitis, voice alteration, sinusitis, lower respiratory tract infection, hiccup<sup>[Ref]</sup></p><p id="ref_1">1. Cerner Multum,  Inc. "UK Summary of Product Characteristics." O 0</p><p id="ref_2">2. Cerner Multum,  Inc. "Australian Product Information." O 0</p><p id="ref_3">3. "Product Information. Targiniq ER (naloxone-oxyCODONE)." Purdue Pharma LP, Stamford, CT. </p><h2>More about naloxone / oxycodone</h2><ul class="more-resources-list more-resources-list-general">
<li>During Pregnancy</li>
<li>Dosage Information</li>
<li>Drug Interactions</li>
<li>3 Reviews</li>
<li>Drug class: narcotic analgesic combinations</li>
</ul><h3>Consumer resources</h3><ul class="more-resources-list more-resources-list-consumer">
<li>Advanced Reading</li>
</ul><h3>Professional resources</h3><h3>Related treatment guides</h3><ul class="more-resources-list more-resources-list-conditions">
<li>Pain</li>
</ul><h2>Further information</h2><p class="ddc-disclaimer">Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.</p><p>Some side effects may not be reported. You may report them to the FDA.</p><p class="ddc-disclaimer-link">Medical Disclaimer</p>